2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Nina Shah, MD, discusses ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.
Nina Shah, MD, a hematologist and associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.
Idecabtagene vicleucel (ide-cel; bb2121) and JNJ-4528 are similar in the way they target BCMA and intracellularly signal 4-1BB, Shah explains. This could be very beneficial to patients with multiple myeloma as BCMA is uniformly expressed on myeloma plasma cells.
However, these products differ in terms of structure, Shah adds. For example, the BCMA-directed component of ide-cel attaches to 2 different parts of the target.
Notably, recent findings suggest that even patients with low levels of BCMA can respond to BCMA-directed CAR T-cell therapy, Shah concludes.